| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
YORVIPATH is a prodrug of parathyroid hormone (PTH [1-34]), administered once daily, designed to provide continuous exposure to...
Cantor Fitzgerald analyst Li Watsek reiterates Ascendis Pharma (NASDAQ:ASND) with a Overweight and maintains $170 price target.
Oppenheimer analyst Leland Gershell upgrades Ascendis Pharma (NASDAQ:ASND) from Perform to Outperform and announces $180 pri...
Citigroup analyst David Lebowitz maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $193 to...
JP Morgan analyst Jessica Fye maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $17...
Ascendis Pharma reported disappointing Q2 sales of $38.76 million, missing the consensus of $92.7 million. Key updates included...
TD Cowen analyst Yaron Werber maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $175 to $157.
B of A Securities analyst Tazeen Ahmad maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $...
